Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Gene Therapy Follow-Up: Balance Data Needs And Patient Burden, Bluebird Bio Exec Says
Dec 19 2024
•
By
Kate Rawson
The FDA often requires 15 years of postmarket follow-up for approved gene therapies.
(Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Cell & Gene Therapies
More from R&D